Dr. Reddy's Laboratories Limited has informed the Exchange about Investor Presentation
DRREDDY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dr. Reddy's Laboratories filed its Q4 and FY25 audited financial results presentation with the exchanges. For Q4 FY25, the company posted record quarterly revenue of ₹8,506 crore (up 20% year-on-year) and highest-ever quarterly EBITDA of ₹2,475 crore at 29% margin (up 32% YoY), with PAT of ₹1,594 crore rising 22% YoY. For full-year FY25, revenue grew 17% to ₹32,554 crore, with EBITDA of ₹9,213 crore (28% margin) and PAT of ₹5,654 crore. Growth was broad-based across geographies, with Europe surging 145% YoY (helped by the acquired NRT business), India up 16%, and Emerging Markets up 16%. The company closed FY25 with a net cash surplus of ₹2,454 crore and RoCE of 28%. Strategic updates included UK integration of the NRT business, biosimilar partnerships with Henlius and Bio-Thera, and USFDA acceptance of its Denosumab biosimilar filing.
A strong quarterly and full-year print with record revenues, profits, and a healthy net cash position signals operational strength and should be viewed positively by investors. The filing itself is a routine regulatory disclosure of the investor presentation accompanying the results, so the immediate stock reaction will depend on how the markets digest the underlying numbers and guidance on the earnings call.